The KIF4A Knockout HAP1 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population harboring a targeted disruption of the KIF4A gene in the HAP1 host cell background. This engineered cell pool enables functional interrogation of KIF4A-dependent mechanisms in a genetically tractable human model. The polyclonal format yields a heterogeneous mixture of knockout genotypes derived from bulk gene editing without single-cell cloning, providing a robust population-level loss-of-function resource. The gene disruption is achieved via CRISPR/Cas9-mediated targeting, generating a null KIF4A allele that abrogates expression of the chromokinesin protein. Researchers can utilize this model to dissect KIF4A??s roles in mitotic progression, chromosome dynamics, and tumor cell biology without the confounding effects of wild-type protein activity.
HAP1 is a near-haploid human cell line originally isolated from the KBM-7 chronic myeloid leukemia (CML) clone. These cells exhibit an adherent, fibroblast-like morphology and maintain a largely haploid karyotype, except for a disomic chromosome 15 region. The haploid nature simplifies gene targeting, as a single allele disruption is sufficient to produce functional knockouts, making HAP1 a preferred host for CRISPR-based screens and reverse genetics. Derived from a CML background, HAP1 retains characteristics relevant to hematopoietic malignancies, yet its epithelial-like growth and stable karyotype support a broad range of cell biological assays. This combination of haploid genetics and cancer origin positions HAP1 as an invaluable platform for investigating genes involved in proliferation, genomic stability, and oncogenic signaling.
KIF4A encodes a chromokinesin motor protein that coordinates multiple facets of mitosis. It localizes to chromosome arms during prophase and to the spindle midzone in anaphase, where it regulates chromosome condensation and segregation. Mechanistically, KIF4A is phosphorylated by CDK1 and Aurora B kinase, which modulate its activity and dynamic association with chromatin and microtubules. It forms functional complexes with PRC1 and Ki-67 (MK167) to organize the central spindle, and it interacts with condensin I/II to promote chromosome compaction. KIF4A also participates in DNA damage repair pathways, binding to PARP1 and HP1??. Upstream, its expression is driven by E2F transcription factors and FOXM1, positioning KIF4A within cell-cycle-regulated transcriptional networks. Downstream, KIF4A influences microtubule dynamics and cytokinesis regulators such as RhoA. These interactions place KIF4A at a hub of mitotic spindle assembly, chromosome segregation, and cell cycle checkpoint control, with functional links to PLK1 and Aurora kinase signaling.
In the HAP1 context, disruption of KIF4A provides a clean genetic model to evaluate its contribution to mitotic fidelity and genome maintenance. Because HAP1 cells are already transformed with a CML background, KIF4A loss may reveal synthetic vulnerabilities or exacerbate chromosomal instability, mirroring phenotypes observed in KIF4A-deregulated cancers. The polyclonal knockout population allows bulk assessment of KIF4A-dependent processes such as spindle morphology, cell cycle progression, and DNA repair capacity, without clonal artifacts. High-content screening approaches can exploit these cells to identify chemical probes or genetic interactions that rescue or enhance KIF4A loss-associated defects. The near-haploid genome further ensures that recessive phenotypes are penetrant across the population, facilitating efficient phenotypic characterization.
This KIF4A knockout cell product is suitable for a wide array of research applications, including the study of mitotic regulation, chromosome instability mechanisms, and cancer cell proliferation. Typical assays include flow cytometry to assess cell cycle distribution, immunofluorescence microscopy to visualize spindle abnormalities and chromosome misalignment, and western blotting to monitor phosphorylation changes in mitotic targets such as Aurora B substrates. Colony formation and apoptosis assays can quantify long-term growth effects and cell death upon KIF4A loss. Additionally, live-cell imaging enables real-time observation of mitotic delays, and RNA-seq experiments can reveal transcriptional responses underlying compensatory pathways. These polyclonal knockout cells serve as a valuable tool for functional genomics, drug target validation, and preclinical oncology research. For further information, please contact Ascent Research.
